STEMLINE THERAPEUTICS INC
BiotechSTEMLINE THERAPEUTICS INC is a biotechnology company focused on Immunology, Oncology, Dermatology.
FDA Novel Drug Designations
(2018)See 1 novel approval →
STEMLINE THERAPEUTICS INC's Key Drugs
STEMLINE THERAPEUTICS INC's core commercial portfolio centers on ELZONRIS, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
STEMLINE THERAPEUTICS INC's Recent FDA Approvals
New NDA/BLA approvals for STEMLINE THERAPEUTICS INC over the last two years — novel drugs only, excluding generics and label supplements.
STEMLINE THERAPEUTICS INC's Therapeutic Areas
STEMLINE THERAPEUTICS INC's approved drugs and pipeline span 4 therapeutic areas, led by Immunology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
STEMLINE THERAPEUTICS INC's Top Competitors
STEMLINE THERAPEUTICS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PF PRISM CV, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
STEMLINE THERAPEUTICS INC Pipeline Snapshot
STEMLINE THERAPEUTICS INC has 33 active clinical programs from ClinicalTrials.gov — 9 Phase 3, 10 Phase 2 and 14 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ELZONRIS leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/2 completed
- • Speed: 53 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2018-12-21
- Latest
- 2023-07-26
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges